PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33811972-3	2021	Regulatory CD4+ Foxp3+ T cells were expanded while IFN-gamma producing CD4+ T cells were significantly decreased in ruxolitinib-treated recipients.	ruxolitinib	116-127	interferon gamma	Mus musculus	51-60	
33811972-4	2021	Ruxolitinib suppressed not only the production of IFN-gamma from CD4+ T cells and MCP-1 from CD11b+ macrophage/monocytes, but also the proliferation of these cells in vitro.	ruxolitinib	0-11	interferon gamma	Mus musculus	50-59	
33811972-5	2021	Levels of both cytokines (IFN-gamma and MCP-1) were also reduced in the spleen and skin of ruxolitinib-treated recipients in vivo.	ruxolitinib	91-102	interferon gamma	Mus musculus	26-35	
33811972-6	2021	IFN-gamma-induced MCP-1 production and migration of RAW 264.7 cells, a macrophage cell line, were inhibited by ruxolitinib.	ruxolitinib	111-122	interferon gamma	Mus musculus	0-9	
33811972-9	2021	Taken together, these results suggest that ruxolitinib can prevent scl-GVHD by suppressing IFN-gamma produced by T cells and MCP-1 expression in macrophage/monocytes via inhibition of JAK-STAT signaling.	ruxolitinib	43-54	interferon gamma	Mus musculus	91-100	
33803310-3	2021	Here we hypothesized that Ruxolitinib, an FDA-approved JAK inhibitor known to prevent IFN-gamma signaling, could be repurposed for host-directed therapy in AVHF.	ruxolitinib	26-37	interferon gamma	Mus musculus	86-95	
31015190-3	2019	Ruxolitinib inhibits signaling downstream of IFN-gamma, as well as several other JAK-dependent cytokines.	ruxolitinib	0-11	interferon gamma	Mus musculus	45-54	
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	interferon gamma	Mus musculus	108-117	
31015190-6	2019	In both models, ruxolitinib and alphaIFN-gamma reduced inflammation-associated anemia, indicating that ruxolitinib operates in an IFN-gamma-dependent manner to reverse this HLH manifestation.	ruxolitinib	103-114	interferon gamma	Mus musculus	37-46	
31015190-10	2019	Thus, ruxolitinib operates through IFN-gamma-dependent and -independent mechanisms to dampen HLH by targeting the deleterious effects of T cells and neutrophils, with the latter representing an unappreciated and understudied cell type that contributes to HLH pathogenesis.	ruxolitinib	6-17	interferon gamma	Mus musculus	35-44	
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	74-85	interferon gamma	Mus musculus	22-30	
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	74-85	interferon gamma	Mus musculus	153-161	
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	180-191	interferon gamma	Mus musculus	22-30	
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	180-191	interferon gamma	Mus musculus	153-161	
27546300-6	2016	Interestingly, ruxolitinib, especially at a dose of 200 mg/kg, dampened the overproduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-23 and IL-17A), which coincided with boosting the release of the anti-inflammatory cytokine IL-10.	ruxolitinib	15-26	interferon gamma	Mus musculus	143-152